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Abstract
Background: This study aimed at describing the type and dosage of psychopharmaceuticals dispensed to patients
with psychiatric disorders and to assess the percentage of patients treated with antipsychotics and antidepressants,
the associated therapies, treatment adherence, and dosages used in individuals registered at the Psychiatric Disease
Center (PDC), Regional Health Service of Ferrara.
Methods: The analysis focused on therapeutic programmes presented to the Department of Pharmacy of the
University Hospital of Ferrara of 892 patients treated by the PDC (catchment area of 134605 inhabitants). All
diagnoses were made according to International Classification of Diseases (ICD-9). The analysis focused on
prescriptions from September 2007 to June 2009. Data on adherence to prescribed therapy have were processed
by analysis of variance.
Results: Among the patients 63% were treated with antipsychotics and 40% with antidepressants. Among patients
receiving antipsychotics 92% used second-generation antipsychotics (SGAs) whereas the remaining 8% used first
generation antipsychotics (FGAs). Antipsychotic doses were lower than Daily Defined Dose (DDDs), and SGAs were
often given with anticholinergics to decrease side effects. Mean adherence to antipsychotic therapy was 64%.
Among antidepressants, selective serotonin reuptake inhibitors (SSRIs) were the most often prescribed, 55%.
Dosages of these were within the limits indicated by the technical datasheet but higher than DDDs. Only 26% of
patients underwent monotherapy. In antidepressants polytherapy, medication was associated with another
antidepressant, 6% or with an antipsychotic, 51%. Mean adherence to the antidepressant therapy was 64%.
Conclusions: Patients treated with antipsychotics tend to use doses lower than DDDs. The opposite tendency was
noted in patients treated with antidepressants. Only a small percentage of patients (14%) modified their
neuroleptic therapy by increasing the dosage. On the contrary, patients treated with antidepressants mainly tended
to reduce the doses of their drugs. This study highlights the tendency to follow combination therapies, prescribing
SGAs together with anticholinergics in order to minimize extrapyramidal side effects or by combining two
antidepressants. The study showed low adherence for both pharmaceutical therapies, which is typical in the setting
of the analyzed diseases.
Background
Psychiatric disorders including different forms of depres-
sion and psychosis are highly debilitating conditions that
generate strong discomfort in affected patients and a
heavy burden on society as a whole; drugs indicated for
these are expensive and treatment for these patients costs
more than the average cost of care for other common dis-
eases such as diabetes and hypertension.
Several studies [1,2] demonstrated good efficacy of
antipsychotics and antidepressants in alleviating mental
disorders such as schizophrenia, depression, and bipolar
disorder. However, the efficacy of controlling the symp-
toms of these disorders clearly depends on patient
adherence to treatments, which is typically unsatisfac-
tory [3]. * Correspondence: s.bianchi@ospfe.it
Department of Pharmacy, University Hospital of Ferrara, Corso Giovecca 203,
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between prescriptions in the clinical setting of psychia-
tric disorders and recommendations in official guide-
lines. In particular, studies on prescription of drugs have
highlighted the frequent co-prescription of two or more
medications [6-10], including anticholinergics [11,12],
antidepressants, and antiepileptic drugs. Moreover,
further studies [13] have shown that a high percentage
of users receive drugs that affect the CNS above defined
therapeutic ranges [14,15].
In this study, we looked at the patterns of antipsycho-
tic and antidepressant use within the Psychiatric Disease
Centre (PDC), Regional Health Service of Ferrara, Italy.
Method
Study design
This was a descriptive, retrospective single-centre study
focusing on drugs prescribed by the psychiatrists of the
PDC, with a catchment area of 134605 inhabitants, and
dispensed by the Department of Pharmacy of the Uni-
versity Hospital of Ferrara.
The study mainly focused on patients treated at the
PDC with antipsychotics (Anatomical Therapeutic Che-
mical [ATC] N05) and antidepressants (ATC N06), even
when associated with CNS-active drugs (ATC N). ATC
is a classification system in which drugs are divided into
different groups depending on the organ and their che-
mical, pharmacological, and therapeutic properties. Drug
prescriptions including CNS-inactive drugs were not
taken into account.
The observation period was 26 months from March
2007 to 31 May 2009. The number of patients evaluated
during the evaluation period was 911.
Since the diagnoses for 21% of patients were incom-
plete, it was not possible to obtain definitive diagnoses
for all patients considered in the study. Furthermore, 19
patients (2%) were ineligible for the study because they
did not take drugs specified in the inclusion criteria
mentioned above. Therefore, the total number of
patients eligible for this study was 892 (98%). Drugs pre-
scribed to patients treated by the PDC were all dis-
pensed by the hospital pharmacy.
Subjects
This study was approved by the Ethics Committee of
Ferrara on 28/07/2011 and conducted by applying the
legislative decree of June 24, 2003, no. 211 of Good
Clinical Practice in clinical trials of medicines for clini-
cal use. The study was conducted in accordance with
the Declaration of Helsinki.
Efficacy and safety assessment
This study aimed to assess the use of antipsychotic agents
(ATC N05) and antidepressants (ATC N06) dispensed to
patients treated at the PDC, Regional Health Service of
Ferrara. More specifically, it aimed to assess:
￿ clinical characteristics of patients;
￿ type of drugs prescribed and their dosage;
￿ doses used compared with those indicated by drug
technical datasheets (Summary Product Characteris-
tics; SPC) and the Daily Defined Dose (DDD) [16];
￿ potential modifications to therapy (change of active
drugs and their doses or addition of other active
drugs);
￿ percent patients treated with polytherapy and ana-
lysis of the most frequent combinations;
￿ patient adherence to prescribed therapies, calcu-
lated as percentage drugs consumed versus quantity
prescribed.
Description of instruments
Patients treated at the PDC obtained drugs prescribed
by psychiatrists from the Department of Pharmacy of
the University Hospital of Ferrara. The pharmacist com-
pleted the dispensation database including the following
information: patient data (name, date of birth); prescrib-
ing specialist; diagnosis (coded as ICD-9), prescription
(limitation period; prescribed medication; dosage; phar-
maceutical form; routes of administration; active sub-
stance or drug); and amount of medication dispensed
calculated on the basis of previous drug dispensations.
From that database, we analyzed the following data:
overview of patient data, pathology according to ICD-9,
prescribing centre, number of tablets/capsules/vials dis-
tributed, duration of prescription, daily dosage, quantity
consumed. All variations made by doctors on patients’
prescriptions concerning routes and time of administra-
tion were also taken into account.
We calculated the minimum, average, and maximum
doses of the psychopharmaceuticals used in therapies
and compared them with the DDDs as well as the mini-
mum and maximum dosages of typical and atypical
drugs listed in the SPCs.
Being the only daily average dosage internationally
recognized, the DDD value was chosen as a parameter
to compare daily dosages of therapy. Moreover, the
dosage corresponding to the maximum frequency used
in therapy was calculated for each drug.
Patient level of adherence to prescribed therapies was
also assessed, calculated as the ratio between the
amount of drug they actually withdrew to that pre-
scribed by the doctor.
Statistics
Data on adherence to prescribed therapy were assessed
by analysis of variance (ANOVA). Adherence was
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asses whether is a difference in adherence of the various
molecules. For statistical analysis we used SPSS 18
software.
A t-test was performed on the average adherence of
patients treated with FGAs compared with SGAs.
Results
Patients
A total of 892 patients were eligible for the study (M/F,
362/530); their clinical characteristics are shown in
Table 1.
Mood disorders (especially major depressive disorder
and bipolar disorder) and schizophrenia were the most
frequently diagnosed conditions, accounting for 36% and
35%, respectively, for a combined total of 72% of all
diagnoses (Table 2).
Antipsychotics
In all, 63% of patients (564/892) were prescribed antipsy-
chotics; 42% of them (235/564) were men and 58% (329/
564) women. Their age range was 15-98 years and most
(40% of the total) were in the age range 41-60 years,
although a few prescriptions were made to patients aged
<20 years (0.5%) and in their 90s (1%). Mean age of the
analyzed population was 55 years (SD % ± 17).
Type of prescribed drugs
In patients on antipsychotics, 520/564 (92%) took sec-
ond-generation antipsychotics (SGAs) whereas the
remaining 8% (44/564) took first-generation antipsycho-
tics (FGAs). The distribution is shown in Table 3.
Drug doses
Mean doses were consistently lower than those indicated
by the DDDs. Namely, drugs with prescribed doses slightly
lower than the DDDs were: aripiprazole 13.2 mg (DDD, 15
mg); olanzapine 8.6 mg (DDD, 10 mg); risperidone 3.7 mg
(DDD, 5 mg); and haloperidol 3.7 mg (DDD, 8 mg) (Table
4). Drugs with prescribed doses much lower than the
DDDs were: quetiapine 230.6 mg (DDD, 400 mg); cloza-
pine 179.5 mg (DDD, 300 mg); clotiapine 38.6 mg (DDD,
80 mg); levomepromazine 25 mg (DDD, 300 mg); chlor-
promazine 62.5 mg (DDD, 300 mg) (Table 4).
Moreover, the following drugs were prescribed at
doses lower than those described in the SPCs: clozapine
179.5 mg (SPC, 200-450 mg); haloperidol 3.71 mg (SPC,
60 mg); clotiapine 38.6 mg (SPC, 100-120 mg); and levo-
mepromazine 25 mg (SPC 75-300 mg) (Table 4).
Variations in therapy
In all, 16% of the analyzed population (95/564 patients)
changed their drug dosage during therapy: 44/564 patients
(8%) reduced it while 51/564 patients (9%) increased it.
More specifically, increases in prescribed doses of the fol-
lowing drugs were noted: quetiapine (24/51), olanzapine
(17/51), aripiprazole (4/51), haloperidol (3/51) and risperi-
done (3/51). Antipsychotics that were dose-reduced were
olanzapine (25/44), aripiprazole (7/44), quetiapine (6/44),
risperidone (5/44), and haloperidol (1/44).
The originally prescribed drug was switched to other
medication in 14% of patients (81/564). As such, the fol-
lowing antipsychotics were switched: olanzapine 0.8%;
risperidone 4%; quetiapine 3%; aripiprazole 1%; clotia-
pine 0.4%; haloperidol 0.4%; and chlorpromazine 0.2%.
Concomitant medications used with antipsychotics
In all, 427/564 patients (76%) were treated with antipsy-
chotics and other concomitant therapies. Concomitant
Table 1 Features of patients eligible for the study
Parameter n %
Men 362 40.58
Women 530 59.42
Age group
10-20 8 0.93
21-30 50 5.61
31-40 124 13.90
41-50 190 21.30
51-60 167 18.72
61-70 154 17.26
71-80 133 14.91
81-90 61 6.84
91-100 5 0.56
Mean age, years 56 ± 10.09
SD, standard deviation.
Table 2 Diagnosis reported in therapeutic programs and
coded with the ICD-9 system
ICD-
9
Correspondence %
296 Mood disorders 36.4
295 Schizophrenia 35.4
298 Non-organic psychosis 5.6
299 Pervasive developmental disorders 4.7
297 Delusional disorders 4
290 Dementia 3.9
294 Persistent mental illnesses caused by pathologic
conditions
3
292 Mental disorder caused by substances 2.4
293 Temporary mental illnesses caused by pathologic
conditions
2
300 Anxiety disorders 1.42
309 Adaptation reactions 0.85
318.1 Severe mental retardation 0.28
307.1 Anorexia nervosa 0.14
ICD, International Classification of Diseases.
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following: antidepressants 40% (228/564); antiepileptics
16% (88/564); anticholinergic 9% (48/564); antiepileptic
and antidepressant 7% (40/564); anticholinergic and
antidepressant 2% (12/564); anticholinergic and antiepi-
leptic 1% (8/564); and anticholinergic, antidepressant,
and antiepileptic 0.5% (3/564).
Among patients taking an antipsychotic with an anti-
depressant, 83% were on SGAs. Moreover, SGAs were
frequently given with anticholinergics (73%).
Adherence to therapy
Patient adherence to therapy is shown in Table 3; this
parameter was calculated ranging from a minimum of 60%
for risperidone to a maximum of 69% for chlorpromazine.
Mean adherence to treatments was 64% (SD% ± 28).
We used the statistical t-test to evaluate and compare
the average value of first-generation antipsychotic adher-
ence to that of the second generation. For FGAs, the
adherence mean was 66.97 (SD% ± 2.35), while for
SGAs it was 59.89 (SD% ± 5.37). This statistical testing
Table 3 Patients treated with antipsychotics and treatment adherence
Drug n % patients Adherence CI 95% P-value
Minimum Mean Maximum
SGAs
Aripiprazole 43 7.6 7.78 62.07 100 22.6 - 80.1 0.01
Olanzapine 193 34.2 7.78 59.15 100 25.9 - 81.2 0.01
Quetiapine 156 27.7 8.33 66.68 100 27.9 - 88.5 0.01
Risperidone 109 19.3 8.33 59.75 100 29.3 -84.3 0.01
Clozapine 19 3.4 7.8 51.80 100 29.7 - 85.2 0.01
FGAs
Haloperidol 26 4.6 8.33 63.99 100 17.4 - 59.2 0.01
Clotiapine 8 1.4 16 66.38 100 24.3 - 96.5 0.01
Levomepromazine 6 1.1 33.33 68.06 100 32.8 - 87.9 0.01
Clorpromazine 4 0.7 22.22 69.44 100 20.4 - 80.0 0.01
SGA, second-generation antipsychotics;
FGA, first-generation antipsychotic.
Table 4 Antipsychotic dosages in milligrams used in therapy
Drug DDD Dosage SPC Most commonly prescribed dosage,
mg
% Patients with add-on
anticholinergic
Minimum Mean Maximum
SGAs
Aripiprazole 15 2.5 13.16 30 10-30 10 2.3
Olanzapine 10 1.3 8.6 20 5-20 5 6.7
Quetiapine 400 12.5 230.6 1200 200-
800
200 2.6
Risperidone 5 0.5 3.7 9 2-16 2 11
Clozapine 300 25 179.5 450 200-
450
100 10.5
FGAs
Haloperidol 8 1 3.71 8 60 2 27
Clotiapine 80 14 38.6 100 100-
120
50 87.6
Levomepromazine 300 12.5 25 50 75-300 25 0
Chlorpromazine 300 62.5 62.5 100 30-75 50 50.4
Trascrizione fonetica
DDD, Defined Daily Dose;
SPC, Summary of Product Characteristics;
SGA, second-generation antipsychotic;
FGA, first-generation antipsychotics.
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value equal to.038, showing a difference of treatment
adherence among patients receiving the two categories
of antipsychotics, slightly higher for patients using FGAs
compared with patients treated with SGAs.
Antidepressants
Among patients treated with psychopharmaceuticals,
40% (361/892) took antidepressants, among whom 63%
(228/361) were women and 37% (133/361) men. Their
mean age was 55 years (SD% ± 9). The most frequently
observed age group was 41-60 years (43%). However, a
small number of prescriptions to patients aged 21-30
years (5%) and 81-90 years (4%) were also made.
Type of prescribed drugs
Prescribed antidepressants are shown in Table 5. The
most prescribed antidepressant was venlafaxine (24%)
whereas the most prescribed drug category was selective
serotonin reuptake inhibitors (SSRIs) at 55%.
Drug doses
Minimum, mean, and maximum dosages of antidepres-
sants and their comparison versus the DDDs and the
SPCs are displayed in Table 6. The following antidepres-
sants were given at higher doses versus the DDD: citalo-
pram 44.3 mg (DDD, 20 mg); mirtazapine 44.2 mg
(DDD, 30 mg); paroxetine 29.5 mg (DDD, 20 mg); ser-
traline 73.8 mg (DDD, 50 mg); venlafaxine 129.2 mg
(DDD, 100 mg).
Variations in therapy
In all, 52 of 361 patients (14%) modified the dose of
their therapy: 56% (29/52) of patients reduced it, while
the remaining 44% (23/52) increased it.
The following drugs were dose-decreased during the
observation period: 19/361 (5%) cases for venlafaxine; 3/
361 (0.8%) each for citalopram and paroxetine; 2/361
(0.6%) for amitriptyline; and 1/361 (0.3%) each for ser-
traline and clomipramine.
On the other hand, patients who increased their drug
doses were: 10/361 (3%) for citalopram; 4/361 (1%) for
venlafaxine; 3/361 (0.8%) for paroxetine; 2/361 (0.6%)
for sertraline; 1/361 (0.3%) each for mirtazapine, fluoxe-
tine, trazodone, and clomipramine.
In all, 6% of patients (22/361) switched their originally
prescribed medication to other drugs. More specifically,
the following medications were switched to other drugs
during the observation period: citalopram 23%; mirtaza-
pine 18%, sertraline and venlafaxine both 14%; trazodone,
reboxetine, and fluoxetine all 9%; and paroxetine 5%.
Concomitant therapies with antidepressants
Only 26% of patients took antidepressants as monother-
apy. Drugs taken in addition to antidepressants were:
another antidepressant 6% (22/361); antipsychotic 51%
(184/361); antipsychotic and antiepileptic 9% (32/361);
anticholinergic 0.5% (2/361); antiepileptic 4% (13/361);
two antipsychotics 3% (11/361); antipsychotic and antic-
holinergic 0.3% (1/361); and antipsychotic, anticholiner-
gic, and antiepileptic 0.3% (1/361).
Mean adherence to therapy
Mean adherence to therapy was: 81% for reboxetine;
77% for citalopram; 76% for trazodone; 59% for mirtaza-
pine; 58% for paroxetine; 63% for sertraline; 62% for
venlafaxine; and 52% for fluoxetine. Mean overall adher-
ence to treatments was 64% (SD % ± 34).
Discussion
Antipsychotics
Atypical antipsychotics were most frequently prescribed
(92%). Among atypical antipsychotics, olanzapine, que-
tiapine, and risperidone were the most prescribed,
whereas among typical antipsychotics haloperidol was
by far the most taken.
Table 5 Patients treated with antidepressants and treatment adherence
Drug n % patients Adherence CI 95% P-value
Minimum Mean Maximum
Paroxetine 75 20.83 7.78 57.7 100 23.8 - 76.5 0.03
Citalopram 83 23.06 7.78 77.2 100 26.0 - 83.6 0.03
Venlafaxine 87 24.17 8.33 61.65 100 24.1 - 81.2 0.03
Sertraline 29 8.06 8.33 62.80 100 23.7 - 85.3 0.03
Mirtazapine 32 8.89 59.14 59.14 100 25.8 - 82.2 0.03
Trazodone 25 6.94 11.11 75.94 100 24.5 - 83.5 0.03
Fluoxetine 10 2.78 13.33 52.18 93.33 18.9 - 73.1 0.03
Amitriptiline 4 1.11 35.71 43.42 50 37.2 - 49.5 0.03
Clomipramine 6 1.67 14.81 67.72 100 23.1 - 84.3 0.03
Reboxetine 10 2.78 33.33 81.07 100 38.6 - 92.5 0.03
Total 361
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limits indicated by the SPCs. When compared with the
DDDs, although of limited use in such investigations,
doses lower than the DDDs and within the limits indi-
cated by the SPCs can mean two different things: on the
one hand, low doses can be therapeutically successful,
while on the other, their concomitant use allows the
reduction of each individual drug dosage as well as of
side effects. Moreover, we observed one case of a patient
treated with quetiapine at a dosage 1200 mg/day higher
than that suggested in the technical datasheet (200-800
mg).
Our analysis of typical neuroleptic daily dispensations
showed that prescribed mean dosages were nearly all
within the limits indicated by technical datasheets and
the DDDs [17] except for two drugs. Once again, this
suggests that therapeutic results are achievable at low
dosages and that attempts are made to minimize side
effects. The only exception here was chlorpromazine, for
which maximum doses were higher than those indicated
by technical datasheets and the DDDs.
The greatest dosage variations with antipsychotics
during the therapy were seen for quetiapine and
olanzapine.
The study showed that 14% (81/564) of patients on
antipsychotics replaced the initial drug. More specifi-
cally, 74/81 (91%) patients initially treated with SGAs
were switched to other drugs; only 2/81 (2%) patients
replaced the SGAs with FGAs whereas 6% (5/81) of
patients switched from FGAs to SGAs. The most often
replaced drugs were olanzapine, risperidone, and
quetiapine.
The most frequently noted combination therapy was
an antipsychotic (mainly SGAs) and an anticholinergic.
SGA dosages used with anticholinergics were consis-
tently lower than the DDDs. Since the risk of extrapyra-
midal side effects is very low when atypical drugs are
taken, the combination use with anticholinergics would
be unnecessary. However, the combined use of these
drugs was very common and usually higher than FGAs.
This therapeutic choice probably aims at further redu-
cing the onset of side effects.
T h em a j o r i t yo fp a t i e n t sf o llowed prescribed antipsy-
chotic therapy [18] with a low adherence range of 51-
66%.
T h ed i f f e r e n c ei na d h e r e n ce to treatment (slightly
higher among patients treated with FGAs compared
with patients treated with SGAs) was statistically signifi-
cant; however, we recognize the limits of the different
types of patients in terms of disease severity. SGAs are
currently the first choice of treatment; it often happens
that FGAs are reserved to patients as a second choice or
where SGAs are contraindicated. Probably for this rea-
son, these patients are the most monitored by the spe-
cialists and this could be a reason for greater adherence
to therapy for patients treated with FGAs.
In a study by Magliano et al. [6] carried out in 30 Ita-
lian mental health services which included 682 patients
(M/F 469/213), the data, when compared with our
results, revealed some differences. Their study included
patients aged 18-60 years (mean age 37 years) and
among them, 98% of the subjects used antipsychotics
(63% treated with FGAs and 35% with SGAs). In our
study, the recruited patients had a wider age range of
15-98 years (and therefore the average age was 55 years
old) and only 63% used antipsychotic drugs, with a
lower percentage of patients using FGAs (8%) while 92%
were treated with SGAs. In our study, the use of combi-
nation therapy was more widespread than in the data
obtained from the Magliano study, where only 5% of
patients were prescribed an antipsychotic and an antide-
pressant (versus 40% of patients in Ferrara) and 7%
were receiving an antipsychotic and an anticholinergic
(versus 9% in Ferrara).
Antidepressants
The most prescribed antidepressant was venlafaxine
whereas the most prescribed category of antidepressants,
55% of all antidepressants, was the SSRI class. These
data confirm the results highlighted by other studies
[19], which showed that SSRIs are the most prescribed
antidepressants in Italy. This figure has also been con-
firmed by other European studies such as those by Fin-
der [19] and Serna [20]. Our analysis shows that doses
Table 6 Antidepressants dosages in milligrams used in therapy
Drug DDD Dosage Most commonly prescribed dosage, mg SPC
Minimum Mean Maximum
Citalopram 20 10 44.25 60 20 20-60
Mirtazapine 30 15 44.23 45 30 15-45
Paroxetine 20 5 29.54 60 40 20-60
Sertraline 50 30 73.82 180 100 50-200
Venlafaxine 100 37.5 129.2 300 150 75-375
DDD, Defined Daily Dose;
SPC, Summary of Product Characteristics.
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technical sheets but consistently above those indicated
by the DDDs.
During the therapy, a small proportion (14%) of
patients modified their dosage of prescribed drug: 8% of
them reduced it while the remaining 6% increased it.
The most frequently up-titrated antidepressant was cita-
lopram (19% of the total of patients who increased their
therapy) followed by venlafaxine (8%) and paroxetine
(6%). On the other hand, it emerged that the prescribed
dosage of venlafaxine was usually reduced (in 37% of
patients).
Citalopram was apparently not very efficacious based
on our finding that it was dose-increased more than
other drugs despite having a good adherence.
In most cases, antidepressants were prescribed conco-
mitantly with an antipsychotic or another antidepres-
sant, suggesting quite a high comorbidity of depression
and psychosis in patients in this study. The presence of
a number of patients taking two antidepressants conco-
mitantly also suggests that depression symptoms are dif-
ficult to treat successfully with just a single drug.
Conclusion
This retrospective study evaluated the prescription pro-
files of 892 patients treated by the PDC. SGAs were the
most commonly prescribed antipsychotic agents.
Dosages prescribed were usually within those recom-
mended by the drug manufacturers and international
standards. These agents were often used with concomi-
tant therapies, especially with anticholinergics, despite
the reduced risk of extrapyramidal side effects. SSRIs
were the most commonly prescribed antidepressants, at
dosages within the range recommended by suppliers but
higher than the DDDs. Antidepressants were mainly
prescribed in association with a second antidepressant
or an antipsychotic. For both classes of drugs, we
observed an average level of patient adherence to their
therapies, although there have not been many studies
that have investigated adherence to therapy of antipsy-
chotics and antidepressants. Unfortunately, this may
represent a limitation to our study because it does not
allow comparison of our results to those obtained in
other populations.
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